This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Clorox, CBS: New Targets, Estimates

Stocks in this article: ALB AVP CLX

Hain Celestial Group (HAIN) price target was raised at Citigroup to $42 from $34. Accelerating sales, EPS beat and solid outlook, Citigroup said. Maintain Buy rating .

Hain Celestial numbers were increased at UBS through 2012. Company is seeing better sales, and acquisitions are boosting growth, UBS said. Neutral rating and new $34 price target.

Impax Laboratories (IPXL) numbers were raised at Goldman Sachs. Shares now seen reaching $29, and estimates were also boosted, to match the company's new guidance, Goldman said. Neutral rating.

Las Vegas Sands (LVS) price target was lowered at Credit Suisse to $55 from $56. Meaningful upside potential as its properties continue to ramp, Credit Suisse said. Maintain Outperform rating.

Las Vegas Sands estimates were lowered through 2012 at Morgan Stanley. Singapore is not growing as quickly as expected, Morgan Stanley said. Overweight rating and $50 price target.

Mastercard (MA) estimates, target raised at Goldman Sachs. Shares now seen reaching $315. Estimates also increased, as higher volumes are driving margin growth, according to Goldman. Buy rating.

McKesson (MCK) price target was increased to $89 from $85 at Citigroup. Fourth-quarter EPS was inline, and revenue was better than expected, Citigroup said. Maintain Hold rating.

Marathon Oil (MRO) numbers were boosted at UBS. Shares are now seen reaching $60. Estimates were also increased, given better downstream earnings, UBS said. Buy rating.

Genetics (MYGN) numbers were increased at Goldman Sachs through 2013. Company boosted its guidance, though pricing remains uncertain, Goldman said. Sell rating and new $19 price target.

MetroPCS (PCS) estimates, target increased at Goldman Sachs through 2013. Company is leveraged to smartphone momentum, Goldman said. Neutral rating and new $18 price target.

Pfizer (PFE)estimates, target were boosted at Goldman Sachs. Shares now seen reaching $24. Estimates also raised, given expectations for increased buyback activity. Buy rating.

Perrigo (PRGO) estimates, target upped at UBS. Estimates were boosted through 2012. Generic fundamentals remain strong, UBS said. Buy rating and new $100 price target.

Parexel (PRXL) estimates, target were cut at Goldman Sachs. Shares now seen reaching $22. Estimates also lowered, to match the company's new guidance, Goldman said. Neutral rating.

Molson Coors (TAP) numbers were reduced at Goldman Sachs. Shares now seen reaching $52. Estimates also cut, given lower volume and margins, according to Goldman Sachs. Neutral rating.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,446.19 +58.98 0.34%
S&P 500 2,032.35 +2.80 0.14%
NASDAQ 4,708.2790 +26.7820 0.57%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs